In another trial, a combination of the VEGFR2 inhibitor sunitinib and the c-met inhibitor PF-04217903 blocked tumor progression in RT2 mice10; subsequently, a PanNET patient clinical trial was initiated to test the effects of cabozantinib, a single agent targeting both VEGFR2 and c-met11. The gene discussed is KDR; the disease is neoplasm.